Numerous professionals have stated it would be difficult to impossible to document transmission via jet injectors. Hepatitis C most often progresses asymptomatically and would not be detectable without ongoing active surveillance. However, Hepatitis C was not identified until 1989 and a test to identify the virus was not created until 1992, therefore it would have been impossible to document any incidents of transmission prior to 1992.
- Dr. Bruce Weniger, formerly the Lead Researcher on Vaccine Technology within the CDC and known as Mr. Jet Injection, is one of, if not the, leading expert on jet injectors. In Dr. Weniger’s professional opinion, he states,
MUNJIs are inherently unsafe. Their re-use without intervening sterilization of fluid pathways which may be exposed to patient blood or tissue fluid violates established principles that apply to other critical medical devices. One cannot rely of the absence of documented cases of disease transmission beyond the California outbreak. It is unlikely that routine post-marketing surveillance would link sporadic cases to prior MUNJI use (Weniger, 2005).
- In 1977 the Hepatitis Laboratories Division of the Center for Disease Control secretly conducted safety testing upon the Ped-O-Jet injector. The researchers called for “specifically designed prospective seroepidemiologic studies” to assess the risk of hepatitis transmission via jet injectors (CDC, 1977). Yet no one heeded the call.
- In 1994 researchers within the CDC retested the safety of the Ped-O-Jet Injector. They noted, “The detection of rare, silent transmission would have been difficult, however, and likely to have been missed without active surveillance” (Grabowsky et al., 1994). Therefore, just because there were no documented cases does not mean transmission of blood-borne pathogens did not occur.
- In 1996 the CDC and WHO held a conference on jet injector safety, in which participants had noted, “For an asymptomatic infection like hepatitis B, serosurveys would be required to detect transmission of the virus; in the absence of such data, it is impossible to state with any assurance that transmission has not occurred” (Fields, 1996). Hepatitis C most often progresses asymptomatically as well and therefore would not be detectable without ongoing active surveillance.
- The Armed Forces Epidemiological Board, which is an expert advisory board of civilian physicians and scientists that assists the Department of Defense with medically related issues, stated within a January 9th of 1998 memorandum that no active prospective surveillance studies have been performed to uphold the safety record of jet injectors (AFEB, 1998).
- (AFEB, 1998) Armed Forces Epidemiological Board. Recommendation on Jet Injectors. AFEB (15-1a) 98-6. January 9, 1998.
- (CDC, 1977) CDC. DHEW Memorandum: Informal Quarterly Report of October-December 1977. From: Special Investigations Section (Petersen NJ, Bond WW, Carson LA) to: Deputy Director (Favero MS), Hepatitis Laboratories Division, Phoenix, AZ (unpublished).
- (Fields, 1996) Fields R. Participation in Meeting: Jet injectors for immunization; current practice and safety; improving designs for the future. WHO/CDC Meeting. Atlanta, GA. 2-3 October, 1996. Available at: http://pdf.usaid.gov/pdf_docs/PNABZ997.pdf.
- (Grabowsky et al., 1994) Grabowsky M, Hadler SC, Chen RT, Bond WW, de Souza Brito G. Risk of transmission of hepatitis B virus or human immunodeficiency virus from jet injectors and from needles and syringes. Unpublished manuscript draft, dated January 3, 1994.
- (Weniger, 2005) Weniger B. Safety of Multi-use-nozzle Jet Injectors (MUNJIs) for Bloodborne Pathogen Cross-contamination [draft]. Conference Notes. 7 August 2005.